0R15 11395.0 -4.4043% 0R1E 9100.0 1.1111% 0M69 None None% 0R2V 237.0 2.5974% 0QYR 1354.0 2.9266% 0QYP 457.0 0.3293% 0RUK None None% 0RYA 1460.0 1.2483% 0RIH 187.4 -0.213% 0RIH 187.4 -0.213% 0R1O 197.0 9862.0733% 0R1O None None% 0QFP None None% 0M2Z 290.0 0.6071% 0VSO 28.5 -19.9551% 0R1I None None% 0QZI 504.0 0.0% 0QZ0 220.0 0.0% 0NZF None None% 0YXG 172.35 -89.9621%

stocks

Unveiling Three ASX Growth Companies With High Insider Ownership - Kalkine

The Australian stock market is currently experiencing a downturn, with the ASX200 down by 0.45% and most sectors showing declines. Notably, IT and healthcare sectors have faced significant losses, while real estate has shown some resilience amidst recent economic turbulence highlighted by a surprising inflation report. In such a market context, companies with high insider ownership can be particularly compelling as they often indicate that those closest to the business are confident in its long-term potential and are deeply invested in its success.

Top 10 Growth Companies With High Insider Ownership In Australia

Name Insider Ownership Earnings Growth Hartshead Resources (ASX:HHR) 13.9% 86.3% Cettire (ASX:CTT) 28.7% 26.7% Acrux (ASX:ACR) 14.6% 115.3% Botanix Pharmaceuticals (ASX:BOT) 10% 120.9% Plenti Group (ASX:PLT) 12.8% 106.4% Change Financial (ASX:CCA) 26.6% 76.4% Hillgrove Resources (ASX:HGO) 10.4% 45.4% Biome Australia (ASX:BIO) 34.5% 114.4% Liontown Resources (ASX:LTR) 16.4% 52.2% Argosy Minerals (ASX:AGY) 14.5% 129.6%

Click here to see the full list of 89 stocks from our Fast Growing ASX Companies With High Insider Ownership screener.

Underneath we present a selection of stocks filtered out by our screen.

Botanix Pharmaceuticals

Simply Wall St Growth Rating: ★★★★★★

Overview: Botanix Pharmaceuticals Limited, based in Australia, focuses on the research and development of dermatology and antimicrobial products with a market capitalization of approximately A$624.46 million.

Operations: The company generates revenue primarily through its research and development activities in dermatology and antimicrobial products, totaling A$0.44 million.

Insider Ownership: 10%

Return On Equity Forecast: 44% (2026 estimate)

Botanix Pharmaceuticals, despite its small revenue base of A$437K, is poised for significant growth with expected annual profit and revenue increases substantially above the Australian market average. The company's earnings have expanded by 12.5% annually over the past five years and are projected to surge by 120.89% per year moving forward. Recently, Botanix completed a follow-on equity offering raising A$70 million, which may dilute current shareholders but also funds expansion as it approaches new product launches.

Click to explore a detailed breakdown of our findings in Botanix Pharmaceuticals' earnings growth report. In light of our recent valuation report, it seems possible that Botanix Pharmaceuticals is trading beyond its estimated value. ASX:BOT Ownership Breakdown as at Jul 2024

Flight Centre Travel Group

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Flight Centre Travel Group Limited operates as a travel retailer serving both leisure and corporate sectors across various regions including Australia, New Zealand, the Americas, Europe, the Middle East, Africa, and Asia with a market capitalization of A$4.44 billion.



Operations: The company generates revenue primarily through its leisure and corporate travel segments, with A$1.28 billion from leisure and A$1.06 billion from corporate services.

Insider Ownership: 13.3%

Return On Equity Forecast: 22% (2026 estimate)

Flight Centre Travel Group, now profitable, trades at 18.5% below its estimated fair value, highlighting potential undervaluation. With insider ownership aligning interests with shareholders, the company's earnings are set to outpace the Australian market with an 18.8% annual growth rate. Although revenue growth is more modest at 9.7% annually, it still exceeds the national average of 5.4%. The forecasted high Return on Equity of 21.8% in three years underscores strong management efficacy and financial health.

Unlock comprehensive insights into our analysis of Flight Centre Travel Group stock in this growth report. The valuation report we've compiled suggests that Flight Centre Travel Group's current price could be inflated. ASX:FLT Earnings and Revenue Growth as at Jul 2024

Technology One

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Technology One Limited is a company that develops, markets, sells, implements, and supports integrated enterprise business software solutions both in Australia and internationally, with a market capitalization of A$6.06 billion.

Operations: The company generates revenue through three primary segments: software sales contributing A$317.24 million, corporate services at A$83.83 million, and consulting services totaling A$68.13 million.

Insider Ownership: 12.3%

Return On Equity Forecast: 33% (2027 estimate)

Technology One, a growth-oriented firm with high insider ownership, exhibits promising financial health with earnings expected to grow by 14.3% annually, outpacing the Australian market average of 13.8%. While its revenue growth at 11.1% yearly is below the significant threshold of 20%, it still surpasses the national market's 5.4%. The company's price-to-earnings ratio stands at an attractive A$55.3x compared to the industry average of A$61.6x, suggesting potential undervaluation relative to its peers. Recent results show a robust year-on-year revenue increase from A$201 million to A$240.83 million and a net income rise from A$41.28 million to A$48 million, reflecting strong operational performance and profitability.

Get an in-depth perspective on Technology One's performance by reading our analyst estimates report here. The analysis detailed in our Technology One valuation report hints at an inflated share price compared to its estimated value. ASX:TNE Ownership Breakdown as at Jul 2024

Next Steps

Discover the full array of 89 Fast Growing ASX Companies With High Insider Ownership right here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.

Looking For Alternative Opportunities?

Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.

Companies discussed in this article include ASX:BOTASX:FLT ASX:TNE

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

Disclaimer:
This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.

Latest News

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions